Intermountain Healthcare: Pursuing Precision Medicine

Abstract

Headquartered in Salt Lake City, Intermountain Healthcare operates 23 hospitals and hundreds of clinics in Utah and Idaho and provides insurance to approximately 850,000 patients through its insurance arm, SelectHealth. In 2013, Intermountain, known for its commitment to improving health care outcomes and lowering costs by reducing treatment variation, made the surprising decision to invest significant resources in an innovative precision medicine unit, which would provide life-extending, genetically targeted therapies to late-stage cancer patients. Precision medicine was associated with treatment variation and high costs, the latter being of particular concern given that Intermountain often served as both payer and provider for its patients. But Intermountain’s management was convinced by Lincoln Nadauld, MD, PhD, who joined Intermountain’s oncology team in 2013 and spearheaded the creation of Intermountain Precision Genomics (IPG). By 2016, IPG had a cutting-edge genomic sequencing laboratory that provided sequencing services to Intermountain and non-Intermountain physicians, and IPG’s team had conducted research indicating that targeted therapies administered through IPG extended patient lifespans but increased overall costs. Now, in mid-2017, IPG is undergoing a major transition as it prepares to outsource the bulk of its genomic testing volume to Navican Genomics, a for-profit, Intermountain-owned spinoff. As Nadauld contemplates the future of IPG, he must evaluate two exciting opportunities, and students are asked to consider where Nadauld should focus IPG’s resources: should IPG partner with Intermountain’s behavioral health team to conduct joint research on the relationship between genetic markers and antidepressant effectiveness, or should IPG push for the testing of a large biorepository, which will cost $12 million but could lead to the identification of new precision medicine applications? More broadly, students will also need to consider the ways in which IPG complements or conflicts with Intermountain’s mission and culture.

Related Work

Headquartered in Salt Lake City, Intermountain Healthcare operates 23 hospitals and hundreds of clinics in Utah and Idaho and provides insurance to approximately 850,000 patients through its insurance arm, SelectHealth. In 2013, Intermountain, known for its commitment to improving health care outcomes and lowering costs by reducing treatment variation, made the surprising decision to invest significant resources in an innovative precision medicine unit, which would provide life-extending, genetically targeted therapies to late-stage cancer patients. Precision medicine was associated with treatment variation and high costs, the latter being of particular concern given that Intermountain often served as both payer and provider for its patients. But Intermountain’s management was convinced by Lincoln Nadauld, MD, PhD, who joined Intermountain’s oncology team in 2013 and spearheaded the creation of Intermountain Precision Genomics (IPG). By 2016, IPG had a cutting-edge genomic sequencing laboratory that provided sequencing services to Intermountain and non-Intermountain physicians, and IPG’s team had conducted research indicating that targeted therapies administered through IPG extended patient lifespans but increased overall costs. Now, in mid-2017, IPG is undergoing a major transition as it prepares to outsource the bulk of its genomic testing volume to Navican Genomics, a for-profit, Intermountain-owned spinoff. As Nadauld contemplates the future of IPG, he must evaluate two exciting opportunities, and students are asked to consider where Nadauld should focus IPG’s resources: should IPG partner with Intermountain’s behavioral health team to conduct joint research on the relationship between genetic markers and antidepressant effectiveness, or should IPG push for the testing of a large biorepository, which will cost $12 million but could lead to the identification of new precision medicine applications? More broadly, students will also need to consider the ways in which IPG complements or conflicts with Intermountain’s mission and culture.

In late 2016, Paris Wallace, the CEO of Ovia Health, and the rest of the company’s co-founders faced a difficult decision about the best way to grow Ovia Health’s revenue. Founded in 2012, Ovia Health specialized in mobile and web applications in the women’s health space. After building a strong user base with its original app, Ovia Fertility (which helped women conceive by tracking ovulation and other factors), the young company launched a second app, Ovia Pregnancy (which helped women have a healthy pregnancy by tracking various health metrics). Ovia Health’s apps were free to use, and most of the company’s revenue came from charging advertisers to host ads on its native advertising platform. Wallace believed that the family benefits market was a promising growth area, but he was not sure of the best way to enter the market. Recently, a top health benefits provider had offered Ovia Health a multi-million-dollar contract, but Wallace wondered whether Ovia Health could create a better family benefits solution by turning down the contract and selling directly to employers’ HR departments. Participants will need to examine how Ovia Health evolved its strategy over time and decide which growth opportunity was the better choice.

In December 2017, Marc Freed-Finnegan and Jonathan Wall, the co-founders of retail technology company Index, had to discuss the company’s direction as they entered 2018. Five years earlier, Freed-Finnegan and Wall had founded Index after observing the technological advantages that Amazon and other online retailers had over brick-and-mortar retailers. Index’s first product was a customer database tool that allowed brick-and-mortar retailers to collect customer contact information (e.g., email addresses) at the time of checkout. Index soon added automated marketing tools and payment/security tools (e.g., encryption) to its product portfolio. However, selling to large retail chains had proved challenging—many stakeholders were involved in the buying decision, creating a long sales process, and some retailers did not understand why they should trust a small, young company with their payment security. By late 2017, Index had made some changes to reduce the average sales cycle, but there was still room for improvement. Now, Index was preparing to launch a new product, Index Connect, that would essentially allow retailers to pool customer contact data and be more competitive with Amazon. Participants must evaluate whether Index was taking the right approach to sales and marketing and consider how the company could position Index Connect to be a success.